LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

NCT02612194 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Study closed to accrual due to low accrual numbers.

Conditions

Urinary Bladder Neoplasms
Ureteral Neoplasms
Urethral Neoplasms

Interventions

DRUG: Crizotinib

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]